{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:34:38Z","timestamp":1788899678200,"version":"build-2803163510"},"reference-count":164,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.eururo.2019.09.001","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T00:25:06Z","timestamp":1569457506000},"page":"43-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Quality Indicators for Bladder Cancer Services: A Collaborative Review"],"prefix":"10.1016","volume":"78","author":[{"given":"Jeffrey J.","family":"Leow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.F.","family":"Catto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Efstathiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela B.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alon Z.","family":"Weizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alfred","family":"Witjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quoc-Dien","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2019.09.001_bib0005","series-title":"EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS) 2018. European Association of Urology guidelines 2018 edition","author":"Babjuk","year":"2018"},{"key":"10.1016\/j.eururo.2019.09.001_bib0010","series-title":"EAU guidelines on muscle-invasive and metastatic bladder cancer 2018. European Association of Urology guidelines 2018 edition","author":"Witjes","year":"2018"},{"key":"10.1016\/j.eururo.2019.09.001_bib0015","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline","volume":"198","author":"Chang","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0020","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0025","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00345-018-2438-9","article-title":"ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer","volume":"37","author":"Monteiro","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00345-018-2606-y","article-title":"SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer","volume":"37","author":"Leow","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0035","series-title":"National Institute for Health and Care Excellence (NICE) guidelines\u2014bladder cancer: diagnosis and management","author":"NICE","year":"2015"},{"key":"10.1016\/j.eururo.2019.09.001_bib0040","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.6004\/jnccn.2018.0072","article-title":"NCCN guidelines insights: bladder cancer, version 5.2018","volume":"16","author":"Flaig","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.eururo.2019.09.001_bib0045","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0302-2838(02)00068-4","article-title":"Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies","volume":"41","author":"Brausi","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0050","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.eururo.2014.12.002","article-title":"Trends in operative caseload and mortality rates after radical cystectomy for bladder cancer in England for 1998\u20132010","volume":"67","author":"Hounsome","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0055","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/s41416-018-0084-z","article-title":"Health-related quality of life after treatment for bladder cancer in England","volume":"118","author":"Mason","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2019.09.001_bib0060","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.eururo.2017.02.008","article-title":"Changing current practice in urology: improving guideline development and implementation through stakeholder engagement","volume":"72","author":"MacLennan","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0065","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.eururo.2019.01.031","article-title":"Consensus in bladder cancer research priorities between patients and healthcare professionals using a four-stage modified Delphi method","volume":"76","author":"Bessa","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0070","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/MOU.0000000000000511","article-title":"Measuring quality of urology care using a qualified clinical data registry","volume":"28","author":"Gadzinski","year":"2018","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0075","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/MOU.0000000000000406","article-title":"Improving quality through clinical registries in urology","volume":"27","author":"Tyson","year":"2017","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0080","series-title":"NHS. Bladder cancer quality performance indicators\u2014patients diagnosed between April 2014 and March 2017","first-page":"69","author":"Information Services Division (Scotland)","year":"2018"},{"key":"10.1016\/j.eururo.2019.09.001_bib0085","unstructured":"LUGPA. Urology-Specific eClinical quality measure accepted for 2018 MIPS reporting https:\/\/www.urologytimes.com\/article\/urology-specific-quality-measures-are-coming."},{"key":"10.1016\/j.eururo.2019.09.001_bib0090","first-page":"235","article-title":"The LUGPA alternative payment model for initial therapy of newly diagnosed patients with organ-confined prostate cancer: rationale and development","volume":"19","author":"Kapoor","year":"2017","journal-title":"Rev Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0095","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11934-018-0856-2","article-title":"Performance measurement and quality improvement initiatives for bladder cancer care","volume":"19","author":"Ristau","year":"2018","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.eururo.2019.09.001_bib0100","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.urolonc.2016.12.003","article-title":"Quality indicators in the management of bladder cancer: a modified Delphi study","volume":"35","author":"Khare","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0105","doi-asserted-by":"crossref","first-page":"492","DOI":"10.6004\/jnccn.2013.0061","article-title":"Quality indicators in the management of bladder cancer","volume":"11","author":"Montgomery","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.eururo.2019.09.001_bib0110","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.eururo.2011.07.010","article-title":"Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer","volume":"60","author":"Lammers","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0115","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.juro.2012.08.029","article-title":"Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer","volume":"188","author":"Rink","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0120","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.eururo.2012.08.057","article-title":"Smoking reduces the efficacy of intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer","volume":"62","author":"Rink","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0125","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2013.06.010","article-title":"Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature","volume":"65","author":"Crivelli","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2014.06.002","article-title":"The effect of smoking and timing of smoking cessation on clinical outcome in non-muscle-invasive bladder cancer","volume":"33","author":"Grotenhuis","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0140","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Guerin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0145","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0150","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1464-410X.1988.tb04292.x","article-title":"Cephradine prophylaxis in transurethral procedures for carcinoma of the bladder","volume":"62","author":"MacDermott","year":"1988","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0155","first-page":"577","article-title":"[The value of antibiotic prophylaxis in transurethral resection of bladder tumors. Apropos of 61 cases]","volume":"3","author":"Delavierre","year":"1993","journal-title":"Prog Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0160","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.eururo.2008.03.033","article-title":"Antibiotic prophylaxis in urologic procedures: a systematic review","volume":"54","author":"Bootsma","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0165","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.euf.2016.02.010","article-title":"How to use antimicrobial prophylaxis in urological procedures","volume":"2","author":"Cai","year":"2016","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2019.09.001_bib0170","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.eururo.2015.05.010","article-title":"Adherence to European Association of Urology guidelines on prophylactic antibiotics: an important step in antimicrobial stewardship","volume":"69","author":"Cai","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0175","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.juro.2008.01.068","article-title":"Best practice policy statement on urologic surgery antimicrobial prophylaxis","volume":"179","author":"Wolf","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0180","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.euf.2016.03.004","article-title":"The Global Prevalence of Infections in Urology (GPUI) study: a worldwide surveillance study in urology patients","volume":"2","author":"Wagenlehner","year":"2016","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2019.09.001_bib0185","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.juro.2014.01.087","article-title":"The importance of transurethral resection of bladder tumor in the management of nonmuscle invasive bladder cancer: a systematic review of novel technologies","volume":"191","author":"Richards","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0190","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.eururo.2009.05.047","article-title":"Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience","volume":"57","author":"Mariappan","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0195","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.juro.2016.03.151","article-title":"A 10-item checklist improves reporting of critical procedural elements during transurethral resection of bladder tumor","volume":"196","author":"Anderson","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0200","first-page":"8976","article-title":"Improving the quality of operative reports for transurethral resection of bladder tumor surgery in resident education","volume":"24","author":"Haddad","year":"2017","journal-title":"Can J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0205","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/bju.14557","article-title":"Surgical checklist impact on recurrence-free survival of patients with non-muscle-invasive bladder cancer undergoing transurethral resection of bladder tumour","volume":"123","author":"Suarez-Ibarrola","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2019.09.001_bib0210","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/MOU.0000000000000459","article-title":"Novel endoscopic visualization techniques for bladder cancer detection: a review of the contemporary literature","volume":"28","author":"Mari","year":"2018","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0215","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.eururo.2014.06.037","article-title":"Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations","volume":"66","author":"Witjes","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0220","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.eururo.2013.07.007","article-title":"Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature","volume":"64","author":"Rink","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0225","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.eururo.2018.02.014","article-title":"Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review","volume":"73","author":"Cumberbatch","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0230","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.eururo.2009.07.005","article-title":"Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer","volume":"56","author":"Dalbagni","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0235","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.6004\/jnccn.2015.0123","article-title":"Role of repeat resection in non-muscle-invasive bladder cancer","volume":"13","author":"Herr","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.eururo.2019.09.001_bib0240","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1089\/end.2011.0081","article-title":"Repeated white light transurethral resection of the bladder in nonmuscle-invasive urothelial bladder cancers: systematic review and meta-analysis","volume":"25","author":"Vianello","year":"2011","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0245","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.ju.0000070437.14275.e0","article-title":"Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study","volume":"170","author":"Grimm","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0250","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00005392-199907000-00018","article-title":"The value of a second transurethral resection in evaluating patients with bladder tumors","volume":"162","author":"Herr","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0255","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.euf.2016.12.011","article-title":"Role of restaging transurethral resection for T1 non-muscle invasive bladder cancer: a systematic review and meta-analysis","volume":"4","author":"Naselli","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2019.09.001_bib0260","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/bju.13102","article-title":"Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guerin","volume":"116","author":"Baltaci","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2019.09.001_bib0265","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.euf.2017.10.004","article-title":"Long-term outcomes from re-resection for high-risk non-muscle-invasive bladder cancer: a potential to rationalize use","volume":"5","author":"Gordon","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2019.09.001_bib0270","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","volume":"69","author":"Sylvester","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0275","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2018.4657","article-title":"Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial","volume":"319","author":"Messing","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2019.09.001_bib0280","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0022-5347(17)36198-0","volume":"149","author":"Oosterlinck","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0285","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/01.ju.0000168657.51551.49","article-title":"Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer","volume":"174","author":"Brocks","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0290","article-title":"A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials","volume":"171","author":"Sylvester","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0295","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.eururo.2013.06.009","article-title":"Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review","volume":"64","author":"Perlis","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0300","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.urpr.2017.02.002","article-title":"Exploring patterns of mitomycin C use in community practice urology","volume":"5","author":"Mossanen","year":"2018","journal-title":"Urol Pract"},{"key":"10.1016\/j.eururo.2019.09.001_bib0305","series-title":"NCCN guidelines version 4.2019 for bladder cancer","author":"Flaig","year":"2019"},{"key":"10.1016\/j.eururo.2019.09.001_bib0310","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","article-title":"Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial","volume":"174","author":"Martinez-Pineiro","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0315","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/iju.12609","article-title":"Efficacy and tolerance of one-third full dose bacillus Calmette-Guerin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study","volume":"22","author":"Pfister","year":"2015","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0320","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.juro.2015.08.075","article-title":"Randomized controlled study of the efficacy, safety and quality of life with low dose bacillus Calmette-Guerin instillation therapy for nonmuscle invasive bladder cancer","volume":"195","author":"Yokomizo","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0325","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0330","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/MOU.0000000000000544","article-title":"What to do during bacillus Calmette-Guerin shortage? Valid strategies based on evidence","volume":"28","author":"Abufaraj","year":"2018","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0335","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.euf.2018.06.018","article-title":"Manufacturing and the market: rationalizing the shortage of bacillus Calmette-Guerin","volume":"4","author":"Bandari","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2019.09.001_bib0340","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJMp1615697","article-title":"Ensuring access to injectable generic drugs\u2014the case of intravesical BCG for bladder cancer","volume":"376","author":"Davies","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2019.09.001_bib0345","series-title":"NCCN guidelines version 3.2019 for bladder cancer","author":"Flaig","year":"2019"},{"key":"10.1016\/j.eururo.2019.09.001_bib0350","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","article-title":"Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Guerin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer","volume":"69","author":"Arends","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0355","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/S0090-4295(99)00002-3","article-title":"Upper urinary tract tumors developing after treatment of superficial bladder cancer: 7-year follow-up of 591 consecutive patients","volume":"53","author":"Hurle","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2019.09.001_bib0360","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0022-5347(05)67137-6","article-title":"Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups","volume":"164","author":"Millan-Rodriguez","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0365","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.juro.2013.05.020","article-title":"Upper tract imaging surveillance is not effective in diagnosing upper tract recurrence in patients followed for nonmuscle invasive bladder cancer","volume":"190","author":"Sternberg","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0370","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/bju.14064","article-title":"Associations of specific postoperative complications with costs after radical cystectomy","volume":"121","author":"Mossanen","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2019.09.001_bib0375","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00345-018-2181-2","article-title":"Urinary tract infections following radical cystectomy and urinary diversion: a review of 1133 patients","volume":"36","author":"Clifford","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2017.12.025","article-title":"Prophylactic antibiotics following radical cystectomy reduces urinary tract infections and readmission for sepsis from a urinary source","volume":"36","author":"Werntz","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0385","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.clgc.2017.11.004","article-title":"Contemporary patterns of multidisciplinary care in patients with muscle-invasive bladder cancer","volume":"16","author":"Harshman","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2019.09.001_bib0390","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.eururo.2019.09.001_bib0395","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.juro.2012.10.120","article-title":"Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer","volume":"189","author":"Yuh","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0400","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.urolonc.2009.03.021","article-title":"Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer","volume":"29","author":"Porter","year":"2011","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0405","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/cncr.25429","article-title":"Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer","volume":"117","author":"Raj","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2019.09.001_bib0410","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.eururo.2014.01.009","article-title":"Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides","volume":"67","author":"Reardon","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2017.11.015","article-title":"Perioperative chemotherapy for bladder cancer in the general population: are practice patterns finally changing?","volume":"36","author":"Booth","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0420","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/JU.0000000000000445","article-title":"Neoadjuvant chemotherapy is not associated with adverse perioperative outcomes after robot-assisted radical cystectomy: a case for increased use from the IRCC","volume":"203","author":"Aldhaam","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0425","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.euo.2018.03.001","article-title":"Effectiveness of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the current real world setting in the USA","volume":"1","author":"Hanna","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0430","article-title":"Effect of preoperative delay on survival in patients with bladder cancer undergoing cystectomy in Quebec: a population based study","volume":"175","author":"Mahmud","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0435","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-5347(05)64047-5","article-title":"An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma","volume":"169","author":"Sanchez-Ortiz","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0440","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/00365590410029141","article-title":"Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder","volume":"38","author":"May","year":"2004","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0445","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1097\/01.ju.0000086828.26001.ca","article-title":"Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage","volume":"170","author":"Chang","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0450","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bju.14211","article-title":"Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy","volume":"122","author":"Mmeje","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2019.09.001_bib0455","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1002\/cncr.32048","article-title":"Delays in radical cystectomy for muscle-invasive bladder cancer","volume":"125","author":"Chu","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2019.09.001_bib0460","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijrobp.2018.07.2019","article-title":"Safeguarding autonomy of patients with bladder cancer","volume":"103","author":"Yerramilli","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2019.09.001_bib0465","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.eururo.2016.12.002","article-title":"Clinical outcomes of patients with histologic variants of urothelial cancer treated with trimodality bladder-sparing therapy","volume":"72","author":"Krasnow","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0470","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0475","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","article-title":"Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic","volume":"35","author":"Kulkarni","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0480","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ijrobp.2016.08.023","article-title":"Quality of life in long-term survivors of muscle-invasive bladder cancer","volume":"96","author":"Mak","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2019.09.001_bib0485","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2019.09.001_bib0490","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.juro.2017.08.106","article-title":"Incidence, clinicopathological risk factors, management and outcomes of nonmuscle invasive recurrence after complete response to trimodality therapy for muscle invasive bladder cancer","volume":"199","author":"Sanchez","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0495","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejon.2017.03.001","article-title":"Efficacy of preoperative uro-stoma education on self-efficacy after Radical Cystectomy; secondary outcome of a prospective randomized controlled trial","volume":"28","author":"Jensen","year":"2017","journal-title":"Eur J Oncol Nurs"},{"key":"10.1016\/j.eururo.2019.09.001_bib0500","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/21681805.2014.967810","article-title":"Efficacy of a multiprofessional rehabilitation programme in radical cystectomy pathways: a prospective randomized controlled trial","volume":"49","author":"Jensen","year":"2015","journal-title":"Scand J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0505","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/WON.0000000000000118","article-title":"WOCN Society and AUA position statement on preoperative stoma site marking for patients undergoing urostomy surgery","volume":"42","author":"Salvadalena","year":"2015","journal-title":"J Wound Ostomy Continence Nurs"},{"key":"10.1016\/j.eururo.2019.09.001_bib0510","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMsa012337","article-title":"Hospital volume and surgical mortality in the United States","volume":"346","author":"Birkmeyer","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2019.09.001_bib0515","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMsa035205","article-title":"Surgeon volume and operative mortality in the United States","volume":"349","author":"Birkmeyer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2019.09.001_bib0520","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1056\/NEJMsa1010705","article-title":"Trends in hospital volume and operative mortality for high-risk surgery","volume":"364","author":"Finks","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2019.09.001_bib0525","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.eururo.2011.01.037","article-title":"A systematic review and meta-analysis of the relationship between hospital\/surgeon volume and outcome for radical cystectomy: an update for the ongoing debate","volume":"59","author":"Goossens-Laan","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0530","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.euf.2016.03.001","article-title":"Critical review of outcomes from radical cystectomy: can complications from radical cystectomy be reduced by surgical volume and robotic surgery?","volume":"2","author":"Moschini","year":"2016","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2019.09.001_bib0535","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1067\/msy.2001.117139","article-title":"Volume standards for high-risk surgical procedures: potential benefits of the Leapfrog initiative","volume":"130","author":"Birkmeyer","year":"2001","journal-title":"Surgery"},{"key":"10.1016\/j.eururo.2019.09.001_bib0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2012.09.012","article-title":"Is there a relationship between leapfrog volume thresholds and perioperative outcomes after radical cystectomy?","volume":"32","author":"Sun","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0545","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/bju.13929","article-title":"Centralisation of radical cystectomies for bladder cancer in England, a decade on from the\u2019 improving outcomes guidance\u2019: the case for super centralisation","volume":"121","author":"Afshar","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2019.09.001_bib0550","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/bju.12566","article-title":"Association of hospital volume with conditional 90-day mortality after cystectomy: an analysis of the National Cancer Data Base","volume":"114","author":"Nielsen","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2019.09.001_bib0555","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/21681805.2013.787118","article-title":"Impact of hospital volume on local recurrence and distant metastasis in bladder cancer patients treated with radical cystectomy in Sweden","volume":"47","author":"Sabir","year":"2013","journal-title":"Scand J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0560","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/j.juro.2012.08.042","article-title":"Volume outcomes of cystectomy\u2014is it the surgeon or the setting?","volume":"188","author":"Morgan","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0565","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/bju.12638","article-title":"Variation in performance of candidate surgical quality measures for muscle-invasive bladder cancer by hospital type","volume":"115","author":"Corcoran","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2019.09.001_bib0570","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/bju.12288","article-title":"Benefit in regionalisation of care for patients treated with radical cystectomy: a nationwide inpatient sample analysis","volume":"113","author":"Ravi","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2019.09.001_bib0575","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2008.07.031","article-title":"Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology","volume":"55","author":"Shabsigh","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0580","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.eururo.2014.02.036","article-title":"Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial","volume":"66","author":"Lee","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0585","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.euf.2018.08.025","article-title":"Implementation of a perioperative venous thromboembolism prophylaxis program for patients undergoing radical cystectomy on an enhanced recovery after surgery protocol","volume":"6","author":"Chiang","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2019.09.001_bib0590","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.eururo.2017.07.031","article-title":"Prospective implementation of enhanced recovery after surgery protocols to radical cystectomy","volume":"73","author":"Pang","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0595","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ucl.2017.12.007","article-title":"Enhanced recovery after surgery pathways: role and outcomes in the management of muscle invasive bladder cancer","volume":"45","author":"Zainfeld","year":"2018","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.eururo.2019.09.001_bib0600","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.eururo.2016.05.031","article-title":"Enhanced recovery pathways versus standard care after cystectomy: a meta-analysis of the effect on perioperative outcomes","volume":"70","author":"Tyson","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0605","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.eururo.2016.05.020","article-title":"Enhanced recovery after robot-assisted radical cystectomy: EAU Robotic Urology Section Scientific Working Group consensus view","volume":"70","author":"Collins","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0610","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.eururo.2016.02.051","article-title":"Enhanced recovery after urological surgery: a contemporary systematic review of outcomes, key elements, and research needs","volume":"70","author":"Azhar","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0615","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0620","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/cncr.22250","article-title":"Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed?","volume":"107","author":"Koppie","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2019.09.001_bib0625","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1002\/cncr.23474","article-title":"The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy","volume":"112","author":"Wright","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2019.09.001_bib0630","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1200\/JCO.2005.03.084","article-title":"Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor","volume":"23","author":"Fleischmann","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0635","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.eururo.2006.08.014","article-title":"Morbidity from pelvic lymphadenectomy in men undergoing radical prostatectomy","volume":"50","author":"Studer","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0640","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/cncr.25011","article-title":"Effect of a minimum lymph node policy in radical cystectomy and pelvic lymphadenectomy on lymph node yields, lymph node positivity rates, lymph node density, and survivorship in patients with bladder cancer","volume":"116","author":"Fang","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2019.09.001_bib0645","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0022-5347(05)65555-3","article-title":"Impact of separate versus en bloc pelvic lymph node dissection on the number of lymph nodes retrieved in cystectomy specimens","volume":"166","author":"Bochner","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0650","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.urology.2008.03.005","article-title":"Effect of healthcare provider characteristics on nodal yield at radical cystectomy","volume":"72","author":"Kulkarni","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2019.09.001_bib0655","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.eururo.2018.09.047","article-title":"Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial","volume":"75","author":"Gschwend","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0660","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.eururo.2014.01.029","article-title":"Propensity-matched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the United States","volume":"66","author":"Leow","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0665","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1089\/end.2018.0313","article-title":"Comparison of perioperative outcomes between open and robotic radical cystectomy: a population-based analysis","volume":"32","author":"Nazzani","year":"2018","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0670","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/bju.14143","article-title":"Open radical cystectomy in England: the current standard of care\u2014an analysis of the British Association of Urological Surgeons (BAUS) cystectomy audit and Hospital Episodes Statistics (HES) data","volume":"121","author":"Jefferies","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2019.09.001_bib0675","doi-asserted-by":"crossref","unstructured":"Korbee ML, Voskuilen CS, Hendricksen K, et al. Prediction of early (30-day) and late (30-90-day) mortality after radical cystectomy in a comprehensive cancer centre over two decades. World J Urol In press. https:\/\/doi.org\/10.1007\/s00345-019-03011-2.","DOI":"10.1007\/s00345-019-03011-2"},{"key":"10.1016\/j.eururo.2019.09.001_bib0680","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/j.ejso.2014.10.004","article-title":"Contemporary 90-day mortality rates after radical cystectomy in the elderly","volume":"40","author":"Schiffmann","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0685","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.eururo.2013.12.018","article-title":"Prediction of 90-day mortality after radical cystectomy for bladder cancer in a prospective European multicenter cohort","volume":"66","author":"Aziz","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0690","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.juro.2011.09.159","article-title":"Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer","volume":"187","author":"Eswara","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0695","doi-asserted-by":"crossref","first-page":"17258","DOI":"10.18632\/oncotarget.12907","article-title":"Impact of surgical margin status on the outcome of bladder cancer treated by radical cystectomy: a meta-analysis","volume":"8","author":"Hong","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.eururo.2019.09.001_bib0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2007.08.023","article-title":"Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival","volume":"178","author":"Dotan","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0705","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eururo.2013.08.033","article-title":"Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials","volume":"66","author":"Leow","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0710","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","article-title":"Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience","volume":"61","author":"Efstathiou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0715","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.ju.0000169424.79702.6d","article-title":"Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor","volume":"174","author":"Palou","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0720","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrurol.2017.125","article-title":"Characteristics and clinical significance of histological variants of bladder cancer","volume":"14","author":"Moschini","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0725","doi-asserted-by":"crossref","first-page":"E148","DOI":"10.5489\/cuaj.787","article-title":"Age-stratified distribution of metastatic sites in bladder cancer: a population-based analysis","volume":"8","author":"Bianchi","year":"2014","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.eururo.2019.09.001_bib0730","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1200\/JCO.2016.67.9902","article-title":"Is participation in cancer phase I trials really therapeutic?","volume":"35","author":"Kimmelman","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0735","series-title":"Treatment clinical trials for bladder cancer","author":"NCI","year":"2019"},{"key":"10.1016\/j.eururo.2019.09.001_bib0740","series-title":"Ongoing bladder cancer trials. In: UK CR, editor. Cancer research UK","author":"Cancer Research UK","year":"2019"},{"key":"10.1016\/j.eururo.2019.09.001_bib0745","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1001\/jamasurg.2013.4109","article-title":"Composite measures for profiling hospitals on bariatric surgery performance","volume":"149","author":"Dimick","year":"2014","journal-title":"JAMA Surg"},{"key":"10.1016\/j.eururo.2019.09.001_bib0750","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1007\/s00464-018-6191-3","article-title":"Development and validation of surgical training tool: cystectomy assessment and surgical evaluation (CASE) for robot-assisted radical cystectomy for men","volume":"32","author":"Hussein","year":"2018","journal-title":"Surg Endosc"},{"key":"10.1016\/j.eururo.2019.09.001_bib0755","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.urology.2016.06.063","article-title":"Development and validation of a quality assurance score for robot-assisted radical cystectomy: a 10-year analysis","volume":"97","author":"Hussein","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2019.09.001_bib0760","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/bju.13748","article-title":"Development, validation and clinical application of pelvic lymphadenectomy assessment and completion evaluation: intraoperative assessment of lymph node dissection after robot-assisted radical cystectomy for bladder cancer","volume":"119","author":"Hussein","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2019.09.001_bib0765","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/JU.0000000000000282","article-title":"Hospital quality metrics for radical cystectomy: disease-specific and correlated to mortality outcomes","volume":"202","author":"Khanna","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0770","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial","volume":"116","author":"Di Lorenzo","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2019.09.001_bib0775","article-title":"Intravesical gemcitabine for non-muscle invasive bladder cancer","volume":"1","author":"Jones","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2019.09.001_bib0780","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.eururo.2007.02.063","article-title":"Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma","volume":"52","author":"Friedrich","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0785","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0790","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0022-5347(05)65966-6","volume":"166","author":"van der Meijden","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0795","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0800","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00345-009-0377-1","article-title":"The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience","volume":"27","author":"Barlow","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0805","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/BLC-170126","article-title":"Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer","volume":"3","author":"Milbar","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.eururo.2019.09.001_bib0810","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.urolonc.2008.11.019","article-title":"Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer","volume":"28","author":"Breyer","year":"2010","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0815","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.juro.2016.12.090","article-title":"Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis","volume":"197","author":"Chou","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.09.001_bib0820","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283819306906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283819306906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:07:01Z","timestamp":1759583221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283819306906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":164,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0302283819306906"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2019.09.001","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality Indicators for Bladder Cancer Services: A Collaborative Review","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2019.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}